IMA Clinical Research Warren

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Obesity7 trials
• Type 2 diabetes4 trials
• Lyme disease3 trials
• Alzheimer disease1 trial
• Coronary artery disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial

Phase

• Phase 313 trials

Status

• Recruiting5 trials
• Active, not recruiting4 trials
• Completed3 trials
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company9 trials
• Pfizer3 trials
• Amgen1 trial

Running trials

• Recruiting

  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07881458· Phase 3· Eli Lilly and Company· Source

  Contact: Samar Hameed (principal investigator)

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: Nancy Phillips (principal investigator)

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  NCT07321886· Phase 3· Eli Lilly and Company· Source

  Contact: Nancy Phillips (principal investigator)

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  NCT07282600· Phase 3· Eli Lilly and Company· Source

  Contact: Nancy Phillips (principal investigator)

• Active, not recruiting

  A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

  NCT07226882· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

  NCT07232719· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Nancy Phillips (principal investigator)

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity4 recruiting
• Type 2 diabetes3 recruiting
• Coronary artery disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting

Closed trials

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Eli Lilly and Company· Source

• Completed

  Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

  NCT05634811· Phase 3· Pfizer· Source

• Completed

  An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Phase 3· Pfizer· Source